Adjuvant Palbociclib in Elderly Patients With Breast Cancer
NCT03609047
Active Not Recruiting
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
01/23/2024
Locations: Cliniques Universitaires Saint-Luc, Brussels, Not set +72 locations
Conditions: Breast Cancer Stage II, Breast Cancer Stage III
Register for Updates
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
NCT02609386
Completed
The purpose of this study is to determine whether a pre-operative regimen of the study drug, IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single dose of cyclophosphamide, followed by 21 days of indomethacin, zinc-containing multivitamins, and omeprazole is active in treatment of oral cavity cancer. The regimen is intended to stimulate an immune response against the cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2024
Locations: Banner University Medical Center, Tucson, Arizona +21 locations
Conditions: Squamous Cell Carcinoma of the Oral Cavity
Register for Updates
Selinexor, Cyclophosphamide and Prednisone in Myeloma
NCT06212596
Completed
The trial is designed as a randomised, controlled, open, parallel group, multi-centre phase II trial to evaluate clinical efficacy of selinexor in combination with cyclophosphamide and prednisone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: Birmingham Heartlands Hospital, Birmingham, Not set +12 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Non-Myeloablative Conditioning and Bone Marrow Transplantation
NCT01850108
Active Not Recruiting
Allogeneic blood or marrow transplantation (alloBMT) is a curative therapy for a variety of hematologic disorders, including sickle cell disease and thalassemia. Even when it is clear that alloBMT can give to these patients an improvement in their disease, myeloablative transplants have important toxicities and mortalities associated. The lack of suitable donors continues to be a limit to access to transplantation. Substantial progress has been made recently in the development of pre-treatment r... Read More
Gender:
ALL
Ages:
Between 1 year and 70 years
Trial Updated:
01/08/2024
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee +2 locations
Conditions: Sickle Cell Disease, Hemoglobinopathies
Register for Updates
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
NCT05848765
Recruiting
The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: NHS Grampian, Aberdeen, Not set +24 locations
Conditions: Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
Register for Updates
Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer
NCT00525759
Completed
There is clear preclinical in vitro and in vivo evidence of sequence dependent synergy between chemotherapy agents and zoledronic acid. The aim of the study is to investigate if the synergistic increase in tumour cell apoptosis observed in preclinical studies occurs in patients. The hypothesis for this study is that there may be anti-tumour benefits of the sequential application of chemotherapy agents followed by zoledronic acid in patients with invasive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Sheffield Teaching Hospitals NHS Foundation Trust / Weston Park Hospital, Sheffield, South Yorkshire
Conditions: Breast Cancer
Register for Updates
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
NCT03197935
Completed
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2023
Locations: Stanford University Medical Center, Palo Alto, California +67 locations
Conditions: Triple-negative Breast Cancer
Register for Updates
A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
NCT03571308
Completed
Previously untreated CD20 positive diffuse large B-cell lymphoma (DLBCL) requiring full course chemoimmunotherapy.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
09/26/2023
Locations: Southampton University Hospitals NHS Tust, Southampton, Hampshire +6 locations
Conditions: Non Hodgkin Lymphoma
Register for Updates
Methods of T Cell Depletion Trial (MoTD)
NCT04888741
Recruiting
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
09/25/2023
Locations: University Hospital of Wales, Cardiff, Wales +14 locations
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelofibrosis
Register for Updates
Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
NCT02431988
Completed
The purpose of this study is to administer novel cluster of differentiation antigen 19 (CD19) specific Chimeric Antigen Receptor T-cells (CAR19 T-cells) to patients with relapsed or resistant Diffuse Large B Cell Lymphoma (DLBCL) to assess the safety and efficacy of this strategy as a bridge to allogeneic transplantation.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
04/26/2023
Locations: University College London Hospital, London, Not set
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
NCT03003520
Completed
This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, and predictive biomarkers of durvalumab in combination with R-CHOP or R2-CHOP, followed by durvalumab consolidation therapy in previously untreated subjects with high-risk diffuse large B-cell lymphoma (DLBCL). Induction treatment with R-CHOP (± lenalidomide) will last for a total of up to 6 to 8 treatment cycles (21 day cycles), and the total time on study treatment, including durvalumab consolidation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +19 locations
Conditions: Lymphoma, Large B-Cell, Diffuse
Register for Updates
TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
NCT01995344
Terminated
This is a two arm, open-labelled phase II randomised trial of Tumour Infiltrating Lymphocytes (TIL) in metastatic melanoma patients given with preconditioning chemotherapy and Interleukin-2 (IL2). Eligible patients will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Patients will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2023
Locations: The Christie NHS Foundation Trust, Manchester, Greater Manchester
Conditions: Metastatic Melanoma
Register for Updates